<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/response-based-dosing-and-mutation-testing-guide-ponatinib-use-in-cml</loc>
      <lastmod>2026-11-19T22:34:54.137Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:34:54.137Z</news:publication_date>
        <news:title><![CDATA[Response-Based Dosing and Mutation Testing Guide Ponatinib Use in CML]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/comparing-dasl-hicap-trial-with-enzarad-and-stampede-trials-and-discussion-of-agent-choice</loc>
      <lastmod>2026-11-19T22:15:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:15:00Z</news:publication_date>
        <news:title><![CDATA[Comparing DASL-HiCaP Trial with ENZARAD and STAMPEDE Trials and Discussion of Agent Choice]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/defining-high-risk-localized-prostate-cancer-and-the-dasl-hicap-trial</loc>
      <lastmod>2026-11-19T22:12:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:12:00Z</news:publication_date>
        <news:title><![CDATA[Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/testing-timing-and-toxicity-maximizing-tepotinib-s-durable-benefit-in-met-exon-14-skipping-nsclc</loc>
      <lastmod>2026-11-19T21:46:21.174Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:46:21.174Z</news:publication_date>
        <news:title><![CDATA[Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/ec-approves-extended-cemiplimab-dosing-in-skin-lung-and-cervical-cancers</loc>
      <lastmod>2026-11-19T21:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:10:00Z</news:publication_date>
        <news:title><![CDATA[EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-janjigian-on-biomarkers-to-guide-first-line-treatment-in-her2-gastroesophageal-cancer</loc>
      <lastmod>2026-11-19T20:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:30:00Z</news:publication_date>
        <news:title><![CDATA[Dr Janjigian on Biomarkers to Guide First-Line Treatment in HER2+ Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dose-optimization-evidentiary-bars-patient-selection-shape-trial-design-egfr-her2-mutant-nsclc</loc>
      <lastmod>2026-11-19T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-grants-priority-review-to-sonesitatug-vedotin-in-cldn18-2-gastroesophageal-cancer</loc>
      <lastmod>2026-11-19T17:19:06.786Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T17:19:06.786Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/induction-chemoimmunotherapy-ctdna-point-beyond-pacific-unresectable-stage-iii-nsclc</loc>
      <lastmod>2026-11-19T15:14:34.403Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:14:34.403Z</news:publication_date>
        <news:title><![CDATA[Induction Chemoimmunotherapy and ctDNA Point Beyond PACIFIC in Unresectable Stage III NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/revisit-every-onclive-on-air-episode-from-october-2026</loc>
      <lastmod>2026-11-19T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Revisit Every OncLive On Air Episode From October 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sclc-treatment-advances-compound-with-egfr--and-kras-directed-nsclc-updates-at-esmo-2026</loc>
      <lastmod>2026-11-19T14:54:22.903Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:54:22.903Z</news:publication_date>
        <news:title><![CDATA[SCLC Treatment Advances Compound With EGFR- and KRAS-Directed NSCLC Updates at ESMO 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/bridging-therapy-considerations-in-dlbcl-before-car-t-cell-therapy</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Bridging Therapy Considerations in DLBCL Before CAR T-Cell Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/unmet-needs-after-immunotherapy-in-endometrial-cancer</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Unmet Needs After Immunotherapy in Endometrial Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/bridging-therapy-before-car-t-cell-therapy-in-dlbcl</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Bridging Therapy Before CAR T-Cell Therapy in DLBCL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-expression-levels-carcinosarcoma-and-tumor-heterogeneity</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[HER2 Expression Levels, Carcinosarcoma, and Tumor Heterogeneity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/elticertinib-receives-fda-fast-track-designation-in-egfr-exon-20-mutated-nsclc</loc>
      <lastmod>2026-11-18T22:11:09.658Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:11:09.658Z</news:publication_date>
        <news:title><![CDATA[Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-daretabart-for-newly-diagnosed-high-risk-neuroblastoma</loc>
      <lastmod>2026-11-18T21:55:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:55:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk Neuroblastoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/exploratory-insights-into-early-tolerability-and-treatment-experience-with-vyloy-zolbetuximab-clzb-in-spotlight-and-glow</loc>
      <lastmod>2026-11-18T19:24:02.712Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:24:02.712Z</news:publication_date>
        <news:title><![CDATA[Exploratory Insights into Early Tolerability and Treatment Experience with VYLOY® (zolbetuximab-clzb) in SPOTLIGHT and GLOW]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/can-ai-fix-clinical-trial-access-in-oncology-arturo-loaiza-bonilla-md-built-the-answer-with-the-data-to-back-it</loc>
      <lastmod>2026-11-18T18:51:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:51:00Z</news:publication_date>
        <news:title><![CDATA[Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/longitudinal-community-training-helps-prepare-oncology-fellows-for-their-future-careers</loc>
      <lastmod>2026-11-18T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/natalee-dellphi-305-interpath-001-and-litespark-012-headline-key-oncology-data-from-esmo-2026</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/galinpepimut-s-improves-os-in-aml-in-second-or-later-remission</loc>
      <lastmod>2026-11-18T14:21:56.157Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:21:56.157Z</news:publication_date>
        <news:title><![CDATA[Galinpepimut-S Improves OS in AML in Second or Later Remission]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/community-care-pathways-in-squamous-nsclc</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Community Care Pathways in Squamous NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/interpreting-subgroup-analyses</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Interpreting Subgroup Analyses]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/detecting-met-driven-resistance-and-the-saffron-survival-data</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Detecting MET-Driven Resistance and the SAFFRON Survival Data]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/emerging-cell-surface-targets-and-neuroendocrine-biomarkers-in-prostate-cancer</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Emerging Cell Surface Targets and Neuroendocrine Biomarkers in Prostate Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/initial-diagnostic-work-up-for-suspected-nets</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Initial Diagnostic Work-Up for Suspected NETs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/updated-kandlelit-001-data-show-durable-responses-with-frontline-calderasib-plus-pembrolizumab</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sequencing-all-comer-regimens-after-first-line-egfr-therapy</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Sequencing All-Comer Regimens After First-Line EGFR Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/evaluating-non-brca-hrr-alterations-for-parp-inhibitor-therapy</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Evaluating Non-BRCA HRR Alterations for PARP Inhibitor Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/patient-centered-treatment-selection-and-shared-decision-making-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Patient-Centered Treatment Selection and Shared Decision-Making in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/somatostatin-receptors-and-circulating-biomarkers-in-nets</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Somatostatin Receptors and Circulating Biomarkers in NETs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/applying-trial-eligibility-to-clinical-practice</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Applying Trial Eligibility to Clinical Practice]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/monitoring-and-managing-ctla-4-toxicities-in-squamous-nsclc</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Monitoring and Managing CTLA-4 Toxicities in Squamous NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/esmo-2026-data-highlight-adc-activity-in-brain-metastases-and-tnbc</loc>
      <lastmod>2026-11-18T01:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T01:00:00Z</news:publication_date>
        <news:title><![CDATA[ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sintilimab-receives-positive-chmp-opinion-for-first-line-nonsquamous-nsclc</loc>
      <lastmod>2026-11-18T00:55:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T00:55:00Z</news:publication_date>
        <news:title><![CDATA[Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC]]></news:title>
      </news:news>
	</url></urlset>